FBFidéline Bonnet-Serrano

Fidéline Bonnet-Serrano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Fidéline Bonnet-Serrano has a total of 177 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Diagnostic utility of diurnal salivary cortisol profiles in neoplastic and nonneoplastic hypercortisolism

    by Fidéline Bonnet-Serrano, Jonathan Poirier, Ralph El Khoury, Louis Thomeret, Nesrine Benanteur, Anne Jouinot, Marie-Clémence Leguy, Anna Vaczlavik, Lucas Bouys, Laurence Guignat, et al.

    Objective: Salivary cortisol has the advantages of being noninvasive, readily accessible in ambulatory patients and reflecting the free bioactive fraction of cortisol. The cortisol diurnal cycle, based on 6 samples collected every 4 h over a 24-h period, allows a detailed characterization of cortisol variations throughout the day. The objective of this study was to assess the value of the salivary cortisol diurnal cycle for the diagnosis of Cushing's syndrome (CS) and the differential diagnosis of nonneoplastic hypercortisolism. Design: This retrospective cohort study included all the patients hospitalized in Endocrinology department of Cochin Hospital between 2012 and 2018 who had complete serum and salivary diurnal cycle assessments. Methods: Serum and salivary cortisol levels were measured using an automated and a radio immunoassay, respectively. Results: A total of 227 subjects without CS, 46 patients with nonneoplastic CS, 72 patients with ACTH-dependent CS, and 67 with adrenal CS were included. For the diagnosis of CS, the cortisol nadir throughout the day showed better diagnostic performance than midnight cortisol, both in serum and saliva with, area under the receiver operating characteristic curves (ROC AUCs) of 0.98 and of 0.96, respectively. For the differential diagnosis between nonneoplastic hypercortisolism and ACTH-dependent CS, salivary cortisol showed better diagnostic performance than midnight serum cortisol (ROC AUC 0.97; optimal cutoff 5.3 nM; sensitivity 90%; and specificity 87% for the salivary cortisol nadir). Conclusion: The salivary cortisol diurnal cycle appears to be a powerful tool for the diagnosis of CS and for the challenging differential diagnosis of nonneoplastic hypercortisolism, with the major advantage of being accessible in ambulatory patients.

  • Open Access

    Genomic characterization of aggressiveness in pituitary neuroendocrine tumors (PitNETs)

    by Nesrine Benanteur, Chiara Villa, Fabio Bioletto, Maria Francesca Birtolo, Daniel De Murat, Julien Masliah-Planchon, Victor Gravrand, Inès Lebib, Mounia Benkhellat, Robin Boezennec, et al.

    Background: Aggressive evolution of PitNETs is rare, metastatic spread even more. Defining aggressiveness and malignancy is challenging, subsequently hard to predict, and to understand. The aim was to provide a molecular definition of aggressiveness using genomic approaches. Methods: PitNETs from 206 patients were included. Associations between 9 clinicopathological features of aggressiveness and PitNETs’ omics were explored. Omics included transcriptome, DNA methylation, chromosomal alterations and mutations. Clonal tumor evolution was monitored in 7 patients. Results: Among the 9 clinicopathological features of aggressiveness, only rapid progression, progression after radiotherapy, Ki67/MIB1 proliferation index ≥10%, temozolomide treatment, metastases and specific death were associated with specific omics signatures, while tumour maximal diameter ≥40mm, cavernous and sphenoid invasion were not. The omic signatures associated with these features of aggressiveness overlapped but remained distinct between corticotroph and mammo-somato-thyrotroph lineages. For each lineage, a common signature of aggressiveness was identified, associating proliferative transcriptome signature and DNA hypermethylation. Alterations in specific genes were associated with aggressive features, - including a novel PitNET gene, LRP1B, and known cancer genes (TP53, CDKN2A) -, while USP8 and GNAS alterations were not. Integration of gene alterations with methylome and transcriptome signatures isolated a subset of molecularly aggressive PitNETs. Molecular signatures were globally stable during the course of the disease, despite evolution towards aggressiveness and potential clonal divergence. Conclusion: This systematic analysis of clinicopathological features of aggressiveness using an integrated multiomic approach establishes a histomolecular definition of aggressiveness in PitNETs. Prospective cohorts studies are needed to validate these molecular signatures and establish their prognostic value.


  • Etude de la stéroïdogénèse des tumeurs bénignes de la corticosurrénale par une approche métabolomique et génomique combinée

    by Fidéline Bonnet-Serrano

    Les cellules de la corticosurrénale expriment les enzymes nécessaires à la synthèse des stéroïdes à partir du cholestérol (glucocorticoïdes et androgènes régulés par l'ACTH hypophysaire ; minéralocorticoïdes sous contrôle du système rénine-angiotensine). Les tumeurs de la corticosurrénale sont fréquentes dans la population générale (prévalence entre 0,5 et 7%). Elles peuvent être unilatérales ou bilatérales dans 8 à 15% des cas et sont bénignes dans plus de 90% des cas. Elles peuvent induire des anomalies symptomatiques de la stéroïdogénèse, en particulier une autonomisation de la sécrétion de cortisol, plus rarement un excès de minéralocorticoïdes ou d'androgènes. L'hyperplasie bilatérale macronodulaire des surrénales (HBMS) est une forme de tumeurs bilatérales bénignes de la corticosurrénale, caractérisée par la présence de plusieurs macronodules bilatéraux de diamètre supérieur à 1 cm. Cliniquement, elle se manifeste par un hypercorticisme de sévérité variable, diagnostiqué en général entre 40 et 65 ans. Les deux principales originalités de l'HBMS reposent d'une part sur l'existence d'une sécrétion intra-surrénalienne d'ACTH et d'autre part sur l'expression de récepteurs illégitimes par les cellules cortico-surrénaliennes, responsable d'une réponse aberrante du cortisol à des stimuli non-physiologiques (Cushing dépendant de l'alimentation liée à l'expression du récepteur au GIP). Une mutation germinale hétérozygote du gène ARMC5 est retrouvée dans 20 à 25% des cas et est associée à un phénotype sévère. L'objectif de notre travail était de caractériser les anomalies de la stéroïdogénèse observées dans les tumeurs bénignes de la corticosurrénale, en particulier l'HBMS par le dosage d'un profil de 18 métabolites urinaires stéroïdiens en GC-MS ainsi que par le dosage d'un profil de 7 stéroïdes sériques en LC-MS/MS avant et après stimulation par l'ACTH 1-24. L'analyse des profils stéroïdiens urinaires de 9 patients atteints d'HBMS, comparés à un groupe de sujets contrôles appariés sur l'âge et le sexe, a permis de mettre en évidence une élévation de certains métabolites urinaires de précurseurs stéroïdiens distribués sur les 3 axes : glucocorticoïdes, minéralocorticoïdes et androgènes ainsi que du cortisol et de la cortisone, y compris chez des patients dont le dosage du cortisol libre urinaire était normal. Les altérations du métabolome urinaire permettraient ainsi un diagnostic plus précoce que les examens de routine. Par ailleurs, l'activité de la CYP11B1, évaluée par un ratio de métabolites, était diminuée chez les patients atteints d'HBMS (résultat à la limite de la significativité du fait du faible effectif). L'analyse des profils stéroïdiens sériques a été réalisée chez 37 patients présentant une atteinte bilatérale des surrénales (BL) (8/37 avec mutation ARMC5), comparés à 38 patients présentant une tumeur unilatérale (UL) et 37 sujets contrôles (CT). L'amplitude de réponse à l'ACTH des 7 stéroïdes étudiés était plus importante dans les BL que dans les UL et les CT. Cette amplification de la réponse n'était pas corrélée à l'augmentation du volume surrénalien, la différence entre les BL et les UL persistant après appariement sur le volume surrénalien, quantifié précisément par une méthode de segmentation manuelle. L'activité des enzymes de la stéroïdogénèse les plus distales sur les 3 axes (CYP11B1/glucocorticoïdes, CYP11B2/minéralocorticoïdes et CYP17A1/androgènes) était au contraire diminuée dans les BL par rapport aux UL et aux CT, permettant de limiter la synthèse des molécules de stéroïdes bioactives (cortisol et androsténedione). Ce phénomène était encore plus marqué chez les patients mutés ARMC5. L'augmentation du volume surrénalien observée dans l'HBMS est longtemps asymptomatique grâce à des mécanismes de compensation, reposant sur une diminution de l'activité des enzymes distales de la stéroïdogénèse qui permettent de limiter la synthèse des molécules bioactives, en particulier le cortisol.

  • The Proteome of Bilateral Macronodular Adrenocortical Disease (BMAD) Shows Different Profiles Correlating with the Genetic Causes and Reveals Specific Dysregulation of RNA Polymerase II and Cholesterol Biosynthesis Enzymes

    by Florian Violon, Anne Jouinot, Bruno Ragazzon, Patricia Vaduva, Lucas Bouys, Louis Thomeret, Johanna Bruce, Marjorie Leduc, Martin Gaillard, Guillaume Assié, et al.


  • Open Access

    Impact of steroid differentiation on tumor microenvironment revealed by single-nucleus atlas of adrenal tumors

    by Anne Jouinot, Yoann Martin, Florian Violon, Thomas Foulonneau, Yanis Bendjelal, Philip Calvet, Brigitte Izac, Franck Letourneur, Céline Bertholle, Muriel Andrieu, et al.

    Adrenocortical carcinomas (ACC) are aggressive and resistant to medical treatment. This study reports a single-nucleus transcriptome atlas of steroid and microenvironment cells in 38 human normal adrenals and adrenocortical tumors. We identify intermediate-state cells between glomerulosa and fasciculata, a transition state in the centripetal trans-differentiation of normal steroid cells. In tumors, steroid cells show expression programs reflecting this zonation. Although ACC microenvironment is scarce, its signatures combine with those of steroid cells into ecotypes. A first ecotype combines cancer-associated fibroblasts, tumor-associated endothelial cells, with hypoxia and mitosis signatures in steroid cells. Another ecotype combines exhausted T cells, with fasciculata steroid signature. These ecotypes are associated with poor survival. Conversely, a third ecotype combines inflammatory macrophages, with reticularis steroid signature, and better outcome. These steroid/microenvironment cells interplays improve outcome predictions and may open therapeutic options in aggressive ACC, through immune microenvironment activation by modulating glucocorticoids/androgens balance.


  • Transcriptomic classification of prolactinomas and somatotropinomas identifies subtypes with variable resistance to treatment

    by Fabio Bioletto, Nesrine Benanteur, Maria Francesca Birtolo, Victor Gravrand, Yoann Martin, Margot Lombard, Karine Perlemoine, Fidéline Bonnet-Serrano, Anne Jouinot, Mirella Hage, et al.

    Objective: Dopamine agonists and somatostatin analogs are commonly used in prolactinomas and somatotropinomas. Response to these therapies is heterogeneous. Whether resistance is linked to specific tumor subtypes or to shared mechanisms of resistance is not known. The aim was to explore distinct molecular subtypes of prolactinomas and somatotropinomas and their association with response to treatment. Methods: The transcriptome of 46 prolactinomas and 58 somatotropinomas was analyzed. Unsupervised classifications were generated and tested for association with histological and clinical data, including response to treatment. Results: Four subtypes of prolactinomas were identified, with variable sensitivity to dopamine agonists (P < 10−4). Sensitive tumors accumulated in the subgroup with the highest DRD2 expression, while resistant tumors accumulated in the 3 remaining ones, enriched in genes related to cAMP metabolism, to mitochondrial and ribosomal activity, and to immunity, respectively. Sparsely granulated somatotropinomas (N = 16) presented a separated molecular entity, mixing tumors resistant and sensitive to somatostatin analogs. The remaining somatotropinomas were classified into 5 subtypes, with variable sensitivity to somatostatin analogs (P < 10−4). Sensitive tumors accumulated in 3 subgroups, characterized by GNAS somatic mutation, PIT1 and SF1 coexpression, and the stem-cell marker SOX2 expression, respectively. Resistant tumors accumulated in the 2 remaining ones, enriched in genes related to cell cycle and to mesenchymal differentiation, respectively. Somatostatin receptor 2 (SSTR2) expression was associated with response to somatostatin analogs in sparsely granulated somatotropinomas (P = .022), but not in other somatotropinomas (P = .923). Conclusions: Prolactinomas and somatotropinomas were classified into distinct transcriptomic groups. Resistance to medical therapies was linked to distinct tumor subtypes, suggesting distinct mechanisms of resistance.


  • Unexpected discrepancies between steroid intra-tissular content in adrenal tumors and clinical diagnosis of steroid excess

    by Fidéline Bonnet-Serrano, Louis Thomeret, Nesrine Benanteur, Patricia Vaduva, Florian Violon, Lucas Bouys, Bruno Ragazzon, Annabel Berthon, Karine Perlemoine, Hortense Wilmot-Roussel, et al.

    Objective: Adrenocortical tumor (ACT) morbidity is associated with steroid secretion, depending on tumor type. Indeed, adrenal steroidogenesis is a finely regulated process, altered in ACT. These alterations are usually characterized by blood steroid assays, also depending on steroid gonadal production and metabolism. Our aim was to determine steroid content directly in ACT tissues and to compare it with clinical diagnosis of steroid excess. Methods: A profile of 13 steroids was analyzed in ultra-high-performance liquid chromatography coupled to tandem mass spectrometry (Thermo Fisher Scientific®) in frozen tissue samples from 75 ACT, 7 Cushing's disease, and 9 normal adrenals. Results: Steroid levels were 10-1000 times higher in tissue from normal adrenal than normal concentrations expected in blood. Concentration ratios between tissue from normal adrenal and blood reference values were lower for distal products than for steroid precursors. In adrenocortical cancers, intra-tissular steroid content was lower than in unilateral benign tumors despite clear clinical steroid excess. Unexpectedly, in overt-Cushing adenomas, intra-tissular cortisol levels were not higher and androstenedione levels were not lower than in non-functioning adenomas. Adrenal differentiation score based on transcriptome was well correlated with intra-tissular cortisol levels. Conclusion: Discrepancies observed between steroid levels measured in ACT tissue and clinical diagnosis of steroid excess suggest a dysregulation of steroid export depending on tumor type, opening new perspectives for diagnosis and treatment of steroid excess.


  • Carney complex predisposes to breast cancer: prospective study of 50 women

    by Patricia Vaduva, Florian Violon, Anne Jouinot, Lucas Bouys, Stéphanie Espiard, Fidéline Bonnet-Serrano, Marie Odile North, Catherine Cardot-Bauters, Gerald Raverot, Sylvie Hieronimus, et al.

    Carney complex (CNC) is a rare genetic syndrome, mostly due to germline loss-of-function pathogenic variants in PRKAR1A. Carney complex includes pigmented skin lesions, cardiac myxomas, primary pigmented nodular adrenocortical dysplasia, and various breast benign tumors. The present study was designed to describe the characteristics of breast lesions in CNC patients and their association with other manifestations of CNC and PRKAR1A genotype. A 3-year follow-up multicenter French prospective study of CNC patients included 50 women who were analyzed for CNC manifestations and particularly breast lesions, with breast imaging, genotyping, and hormonal settings. Among the 38 women with breast imaging, 14 (39%) had breast lesions, half of them bilateral. Ten women (26%) presented with benign lesions and six with breast carcinomas (16%): one had ductal carcinoma in situ at 54, and five had invasive cancer before 50 years old, whom one with contralateral breast cancer during follow-up. The occurrence of breast cancer was more frequent in women with PRKAR1A pathogenic variant odds ratio = 6.34 (1.63-17.91) than in general population of same age. The mean age at breast cancer diagnosis was 44.7 years old: 17 years younger than in the general population. Breast cancer patients had good prognosis factors. All breast carcinomas occurred in individuals with familial CNC and PRKAR1A pathogenic variants. Loss of heterozygosity at the PRKAR1A locus in the 2 invasive breast carcinomas analyzed suggested a driver role of this tumor suppressor gene. As CNC could predispose to breast carcinoma, an adequate screening strategy and follow-up should be discussed in affected women. ClinicalTrial.gov NCT00668291.


  • Proinsulin: physiology, measurement, and interest in clinical biology

    by Katia Carvalho Alves, Fidéline Bonnet-Serrano, Christelle Laguillier, Vanessa Akiki, Léa Dehghani, Étienne Larger, Marie-Clémence Leguy, Jean Guibourdenche

  • Open Access

    Urinary Free Cortisol Determination and Interferences Studies Using Liquid Chromatography Coupled to Tandem Mass Spectrometry after On-Line Solid Phase Extraction Based on TurboflowTM Chromatography

    by Fidéline Bonnet-Serrano, Samir Nakib, Corinne Zientek, Laurence Guignat, Jean Guibourdenche, Jerôme Bertherat, Marie-Claude Menet

    (1) A 24 h urinary free cortisol (UFF) is one of the first-line exams recommended for the diagnosis of Cushing’s syndrome. In a hospital hormonology department, this activity can exceed several hundred dosages per week. The UFF is generally determined via an immunoassay with an automate using a chemiluminescence or electrochemiluminescence detection system. To increase the cortisol concentration in the analyzed sample, the automated analysis is preceded by urine extraction, which does not prevent there from being some interferences due to other steroids with close structures. (2) This paper describes the development of on-line solid phase extraction coupled to liquid chromatography and mass spectrometry for the analysis of urinary free cortisol. The on-line extraction was based on the TurboflowTM chromatography coupled to the analytical column by two valves, easily available for the laboratories. (3) The choice of the Accucore Polar Premium® analytical column made it possible to avoid analytical interferences with exogenous or endogenous molecules having the same SRM transition (363 → 121) as cortisol. (4) The method was fully validated in the range of clinically relevant concentrations from the lower limit of quantification (LLOQ) to 411.75 nmol·L−1.